Sevabertinib (Hyrnuo) is an oral, mutant-selective tyrosine kinase inhibitor approved for adults with HER2-mutant non-small cell lung cancer (NSCLC) who have received prior systemic therapy. By selectively targeting HER2 kinase domain mutations, sevabertinib disrupts tumor-promoting signaling pathways, resulting in significant tumor shrinkage and durable responses. Clinical trials demonstrate a favorable efficacy and safety profile, with […]
Category Archives: Uncategorized
Dordaviprone (Modeyso) is a newly approved targeted therapy for H3 K27M‑mutant diffuse midline glioma, a rare and aggressive brain tumor. Designed as an oral, once-weekly treatment, it employs a dual mechanism: activation of mitochondrial ClpP protease and antagonism of dopamine D2 receptors, inducing tumor cell apoptosis and restoring epigenetic regulation. Approved for both adult and […]
Alpha-Terpinyl Acetate from Elettaria cardamomum: Alzheimer’s disease (AD) is a complex, multifactorial neurodegenerative disorder characterized by progressive cognitive decline, memory impairment, and neuronal loss. Current therapeutic strategies largely focus on single molecular targets and provide only limited symptomatic relief, underscoring the urgent need for disease-modifying approaches. Multi-target directed ligands (MTDLs) have emerged as a promising […]
DNA-dependent protein kinase (DNA-PK) is a critical serine/threonine kinase that plays a central role in preserving genomic integrity. Activated by DNA double-strand breaks, DNA-PK functions as a key regulator of the non-homologous end joining repair pathway, enabling cells to efficiently resolve one of the most lethal forms of DNA damage. Beyond its canonical role in […]
Glycinamide Ribonucleotide Formyltransferase: Deregulated nucleotide biosynthesis is a fundamental metabolic feature of rapidly proliferating cancer cells, making enzymes within the purine de novo pathway attractive therapeutic targets. Glycinamide ribonucleotide formyltransferase (GARFT) catalyzes a critical folate-dependent step in purine synthesis and has been successfully exploited by antifolate inhibitors. Lometrexol, the first selective GARFT inhibitor evaluated clinically, […]
Trimetrexate Glucuronate and Kaposi’s Sarcoma is an angioproliferative malignancy strongly associated with immunodeficiency and human herpesvirus 8 infection, historically presenting a major therapeutic challenge in patients with AIDS. During the early HIV epidemic, treatment strategies for KS were limited by toxicity, immune suppression, and the frequent coexistence of life-threatening opportunistic infections. Trimetrexate glucuronate, a lipophilic […]
Aceclidine is a muscarinic acetylcholine receptor agonist primarily used to manage open-angle glaucoma by reducing intraocular pressure (IOP) through pupil constriction and enhanced aqueous humor outflow. Historically significant in ophthalmology, it offers rapid onset and targeted action, though newer therapies like prostaglandin analogs have largely supplanted its use. Aceclidine remains valuable for patients intolerant to […]
Zongertinib is a novel, highly selective HER2 tyrosine kinase inhibitor developed for the treatment of HER2-mutated cancers, particularly non-small cell lung cancer (NSCLC). Designed to target activating mutations within the HER2 tyrosine kinase domain, zongertinib disrupts oncogenic signaling pathways that drive tumor growth while minimizing off-target toxicity. Clinical trials have demonstrated meaningful and durable antitumor […]
Imatinib Resistance in HES/CEL: Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) are rare hematologic malignancies frequently driven by the FIP1L1-PDGFRα fusion oncogene. Although the tyrosine kinase inhibitor imatinib has demonstrated remarkable clinical efficacy in FIP1L1-PDGFRα–positive patients, the emergence of resistance—most notably due to the T674I gatekeeper mutation—poses a significant therapeutic challenge. This article reviews […]
Remibrutinib in CSU: Chronic spontaneous urticaria (CSU) is a persistent skin condition characterized by recurrent hives and itch, often resistant to antihistamines. Remibrutinib, a novel oral Bruton’s tyrosine kinase (BTK) inhibitor, offers targeted suppression of mast cell and basophil activation, addressing the underlying immune pathways of CSU. Clinical trials demonstrate rapid and sustained symptom relief, […]